Psychiatric News
1998 Annual Meeting


Drug Addiction-A Treatable Disease:
A Special Research-Based Program Track

Presented by APA and the National Institute on Drug Abuse
APA's 1998 Annual Meeting
Toronto, Ontario

The following is a listing of the symposia to be offered in this special track. A total of 30 sessions in a variety of formats round out the track.

Monday, June 1, 2 p.m.--5 p.m.

Symposium 9: Risk and Vulnerability to Drug Abuse
Meyer D. Glantz, Ph.D., chair and discussant
  1. Behavioral Genetic Approach to Drug Abuse Liability Ralph E. Tarter, Ph.D.

  2. Familial Transmission of Drug Abuse and Comorbid Disorders Kathleen R. Merikangas, Ph.D.

  3. Extent of Drug Use and Dependence in the Population Denise Kandel, Ph.D.

  4. First Grade Classrooms: Course of Aggression and Prevention Sheppard G. Kellam, M.D., Xiange Ling, M.S., Rolande Merisca, Ph.D., Hendricks Brown, Ph.D., Nicholas I. Ialongo, Ph.D.

Tuesday, June 2, 2 p.m.-5 p.m.

Symposium 25: Conundrums of Comorbidity Frances R. Levin, M.D., chair; David M. McDowell, M.D., cochair; Edward V. Nunes, M.D., discussant
  1. Treatment of PTSD and Substance Use Disorders Kathleen T. Brady, M.D., Ph.D.

  2. Evaluation of Depression in Substance Abusers David M. McDowell, M.D., Frances R. Levin, M.D, Edward V. Nunes, M.D., Angela Serracini, Ph.D., Herbert D. Kleber, M.D.

  3. Diagnosis and Treatment of Substance Abusers with ADHD Frances R. Levin, M.D., David M. McDowell, M.D., Suzette Evans, Ph.D., Herbert D. Kleber, M.D., Daniel J. Brooks, M.A.

  4. Overcoming Obstacles for Treating Dual Disorders Andrew L. Shaner, M.D., Lisa J. Roberts, M.A., Thad Eckman, Ph.D., John W. Tsuang, M.D., Andrew P. Ho, M.D.

  5. Comorbidity and Outcomes in Substance Abusers John S. Cacciola, Ph.D., Arthur I. Alterman, Ph.D., Megan J. Rutherford, Ph.D., James R. McKay, Ph.D.

Symposium 38: Psychosocial Interventions for Drug Abuse
Stephen T. Higgins, Ph.D., chair; Thomas McLellan, Ph.D., cochair

  1. Contingency Management Therapy with Drug Abusers Stephen T. Higgins, Ph.D.

  2. Therapy for Borderline Personality and Drug Abuse Marsha M. Linehan, Ph.D.

  3. Efficacy of Psychosocial Services for Drug Abuse Thomas McLellan, Ph.D.

  4. Behavioral Couples Therapy for Substance Abuse Timothy J. O'Farrell, Ph.D.

  5. Structured Psychotherapies for Drug Abuse Bruce J. Rounsaville, M.D.

Wednesday, June 3, 2 p.m.-5 p.m.

Symposium 63: Detection and Treatment of Stimulant Abuse David A. Gorelick, M.D., chair
  1. Detection of Stimulant Abuse Jeffrey N. Wilkins, M.D.

  2. Psychosocial Treatment for Stimulant Abusers Douglas M . Ziedonis, M.D.

  3. Pharmacological Treatment of Stimulant Abuse David A. Gorelick, M.D.

  4. Psychiatric Comorbidity in Stimulant Abusers Richard N. Rosenthal, M.D.

  5. Methamphetamine Abuse: New Developments Steven L. Batki, M.D.

Symposium 80: Medications Development for Substance Dependence
Thomas R. Kosten, M.D., chair; Herbert D. Kleber, M.D., discussant

  1. Targeted Subgroups for Cocaine Pharmacotherapies Thomas R. Kosten, M.D.

  2. Targets for Medication to Prevent Relapse Charles P. O'Brien, M.D.

  3. Levomethadyl Acetate Hydrochloride and Buprenorphine Treatment Eric C. Strain, M.D.

  4. Cocaine Pharmacotherapy: Human Laboratory Studies Marian W. Fischman, Ph.D.

  5. Pharmacotherapy for Opiate and Stimulant Dependence Frank J. Vocci, Ph.D.

Thursday, June 4, 2 p.m.-5 p.m.

Symposium 101: Treating Nicotine Dependence in Psychiatric Patients
Michael G. Goldstein, M.D., chair
  1. Motivating Psychiatric Patients to Attempt Smoking Cessation Michael G. Goldstein, M .D.

  2. Smoking Cessation in Patients with Depression Alexander H. Glassman, M.D., Lirio S. Covey, Ph.D.

  3. Treating Nicotine Dependence in Substance-Abusing Patients Raymond S. Niaura, Ph.D.

  4. Treating Nicotine Dependence in Schizophrenia Patients Douglas M. Ziedonis, M.D.

  5. Treating First-Line Failures John R. Hughes, M.D.

Symposium 105: Results of the NIDA Collaborative Cocaine Treatment StudyM
Michael E. Thase, M.D., chair; Paul Crits-Christoph, Ph.D., cochair

  1. Rationale of the NIDA Collaborative Cocaine Treatment Study Lynne Siqueland, Ph.D.

  2. Drug Outcomes of the NIDA Collaborative Cocaine Treatment Study Paul Crits-Christoph, Ph.D.

  3. Secondary Outcomes of the NIDA Collaborative Cocaine Treatment Study Michael E. Thase, M.D.

  4. Dropout in the NIDA Collaborative Cocaine Treatment Study Arlene F. Frank, Ph.D.

  5. Predictors of Outcome of the NIDA Collaborative Cocaine Treatment Study Roger D. Weiss, M.D.

Symposium 112: New Approaches for Opiate Detoxification
Herbert D. Kleber, M.D., chair; Thomas R. Kosten, M.D., cochair; Charles E. Riordan, M.D., discussant